Literature DB >> 17910523

Healing of segmental bone defects by direct percutaneous gene delivery: effect of vector dose.

Volker M Betz1, Oliver B Betz, Vaida Glatt, Louis C Gerstenfeld, Thomas A Einhorn, Mary L Bouxsein, Mark S Vrahas, Christopher H Evans.   

Abstract

Previous studies have demonstrated the ability of direct adenoviral BMP-2 (Ad.BMP-2) gene delivery to enhance bone repair. Nevertheless, in studies using a rat segmental defect model, it has not proved possible to achieve reliably full osseous union in all animals. To address this issue, we evaluated the effect of vector dose on healing. Critical-size defects were created in the right femora of 27 Sprague-Dawley rats. The defects received a single, intralesional, percutaneous injection of 2.7 x 10(7) (low dose), 2.7 x 10(8) (medium dose), or 2.7 x 10(9) (high dose) plaque-forming units of Ad.BMP-2. After 8 weeks, femora were evaluated by X-ray, dual-energy X-ray absorptiometry, microcomputed tomography (microCT), and histology. The high dose of vector bridged 100%, the medium dose 11%, and the low dose 25% of the defects, as evaluated by X-ray and microCT imaging. Bone mineral content and bone volume of the defects receiving the high dose of vector were significantly higher than those of both groups receiving lower doses. Histologically, defects treated with the high dose were filled by trabecular bone and small amounts of cartilage, whereas large areas of fibrous tissue and cartilage remained in the defects receiving lower doses. However, the newly formed bone lacked the structural organization of native bone, suggesting that further maturation is necessary.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17910523     DOI: 10.1089/hum.2007.077

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  18 in total

Review 1.  Direct gene therapy for bone regeneration: gene delivery, animal models, and outcome measures.

Authors:  Gadi Pelled; Ayelet Ben-Arav; Colleen Hock; David G Reynolds; Cemal Yazici; Yoram Zilberman; Zulma Gazit; Hani Awad; Dan Gazit; Edward M Schwarz
Journal:  Tissue Eng Part B Rev       Date:  2010-02       Impact factor: 6.389

Review 2.  Gene therapy approaches to regenerating bone.

Authors:  Nadav Kimelman Bleich; Ilan Kallai; Jay R Lieberman; Edward M Schwarz; Gadi Pelled; Dan Gazit
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

Review 3.  [Bone substitute. Transplants and replacement materials--an update].

Authors:  C Rentsch; B Rentsch; D Scharnweber; H Zwipp; S Rammelt
Journal:  Unfallchirurg       Date:  2012-10       Impact factor: 1.000

Review 4.  Gene therapy for the regeneration of bone.

Authors:  Christopher Evans
Journal:  Injury       Date:  2011-04-13       Impact factor: 2.586

Review 5.  Gene therapy for bone healing.

Authors:  Christopher H Evans
Journal:  Expert Rev Mol Med       Date:  2010-06-23       Impact factor: 5.600

6.  Rapid and reliable healing of critical size bone defects with genetically modified sheep muscle.

Authors:  F Liu; E Ferreira; R M Porter; V Glatt; M Schinhan; Z Shen; M A Randolph; C A Kirker-Head; C Wehling; M S Vrahas; C H Evans; J W Wells
Journal:  Eur Cell Mater       Date:  2015-09-21       Impact factor: 3.942

Review 7.  Current status of gene therapy for rheumatoid arthritis.

Authors:  Daniel F Gaddy; Paul D Robbins
Journal:  Curr Rheumatol Rep       Date:  2008-10       Impact factor: 4.592

Review 8.  Using genes to facilitate the endogenous repair and regeneration of orthopaedic tissues.

Authors:  Christopher Evans
Journal:  Int Orthop       Date:  2014-07-20       Impact factor: 3.075

Review 9.  Efficacy of minimally invasive techniques for enhancement of fracture healing: evidence today.

Authors:  Ippokratis Pountos; Theodora Georgouli; George Kontakis; Peter V Giannoudis
Journal:  Int Orthop       Date:  2010-02       Impact factor: 3.075

10.  Use of genetically modified muscle and fat grafts to repair defects in bone and cartilage.

Authors:  C H Evans; F-J Liu; V Glatt; J A Hoyland; C Kirker-Head; A Walsh; O Betz; J W Wells; V Betz; R M Porter; F A Saad; L C Gerstenfeld; T A Einhorn; M B Harris; M S Vrahas
Journal:  Eur Cell Mater       Date:  2009-12-31       Impact factor: 3.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.